JenKem Beijing R&DJenKem Technology provides high quality PEG aldehyde derivatives for N-terminal PEGylation with high purity and low polydispersity.

JenKem Technology’s activated PEG aldehydes for N-terminal PEGylation are reactive towards the N-terminal amines taking advantage of the lower pKa of the N-terminal amine in proteins.

The sterically bulky structure of JenKem Technology’s proprietary Y-shape branched PEG derivatives, consisting of two linear methoxy PEG chains attached to a central core with an active aldehyde group, may help to reduce the number of attachment sites to a protein molecule. Y-shaped Propionaldehyde PEG is reactive towards N-terminal amines in the presence of a reducing reagent at pH 5-8; less selective but more reactive compared with Y-AALD-40K. Y-shaped Acetaldehyde PEG is an N-terminal amine reactive PEG in the presence of a reducing reagent at pH 5-8; less reactive but more selective compared to linear PEG aldehydes.

Methoxy PEG Propionaldehyde reacts with the N-terminal of proteins such as human granulocyte colony stimulating factor (G-CSF) in filgastrim, at pH 5-8 in the presence of a reducing reagent [12].

N-Terminal PEGylation products with molecular weights, branching, and functional groups not listed in our online catalog may be available by custom synthesis. Please inquire at tech@jenkemusa.com about pricing and availability of custom N-Terminal PEGylation products, and PEGylation services.

JenKem Technology provides GMP grade PEG derivatives and bulk orders via custom synthesis, offering the opportunity to match customers’ special quality requirements. JenKem Technology is capable of development and synthesis of a wide range of GMP PEG derivatives starting at 200g up to 40 kg or greater batches, under ISO 9001 and ISO 13485 certified quality management system, following ICH Q7A guidelines. In 2020 JenKem Technology will transition to use High Purity (> 99%) mPEG Raw Materials to manufacture its GMP grade Methoxy PEG Derivatives. For inquiries on cGMP production of PEG derivatives please contact us at tech@jenkemusa.com.

For global distribution, please visit link. Click the buttons below to order directly from JenKem Technology:

Y-shape Aldehyde PEGs
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
≥ 95% Y-shaped PEG Acetaldehyde reacts with N-terminal amines in the presence of a reducing reagent at pH 5-8. Less reactive but more selective compared to linear PEG aldehyde.
≥ 95% Y-shaped PEG Propionaldehyde reacts with N-terminal amines in the presence of a reducing reagent at pH 5-8. [1-4] Less reactive but more selective compared to linear PEG aldehyde.
Linear Methoxy PEG Aldehydes
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
≥ 95% Methoxy PEG Propionaldehyde is an N-terminal amine reactive PEG. Methoxy PEG Propionaldehyde reacts with N-terminal amines, such as the N-terminal on gsf, rhGCSF, at pH 5-8 in the presence of a reducing reagent. [12]
≥ 95% Methoxy PEG Butyraldehyde reacts with the N-terminal amine on proteins. PEG Butyraldehyde is more stable than PEG Acetaldehyde.
Heterobifunctionahttps://www.jenkemusa.com/product/methoxy-peg-butyraldehydel PEGs Functionalized with Propionaldehyde
References:
  1. Yu, K.-M., et al., Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys, Toxicology and Applied Pharmacology, 2018, V. 342, P. 39-49.
  2. Lorey, S., et al, Novel Ubiquitin-derived High Affinity Binding Proteins with Tumor Targeting Properties, J. Biol. Chem., 2014, 289, 8493-8507.
  3. Liebner, R., et al., Head to Head Comparison of the Formulation and Stability of Concentrated Solutions of HESylated versus PEGylated Anakinra, Journal of Pharmaceutical Sciences, 2015, 104(2): 515-526.
  4. Mayolo-Deloisa, K., et al., Aldehyde PEGylation of laccase from Trametes versicolor in route to increase its stability: effect on enzymatic activity, Journal of Molecular Recognition, 2015, 28(3): 173-179.
  5. Zaykov, A. N., et al., Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice, Peptides, 2019, 120.
  6. Zaghmi, A., et al., Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation, Materials Today Chemistry, 2019, 12:121-31.
  7. Hernandez-Vargas, G., et al., Thermo-separating polymer-based aqueous two-phase systems for the recovery of PEGylated lysozyme species, Journal of Chromatography B., 2019, 1105:120-8.
  8. Behi, J., et al., Optimization of PEGylation reaction time and molar ratio of rhG-CSF toward increasing bioactive potency of monoPEGylated protein, International Journal of Biological Macromolecules, 2018, V. 109, P. 888-895.
  9. Kateja, N., et al., Development of an integrated continuous PEGylation and purification Process for granulocyte colony stimulating factor, Journal of Biotechnology, 2020, 322, p. 79-89.
  10. Zhao, Y.Z., et al., PEGylation with the thiosuccinimido butylamine linker significantly increases the stability of haloalkane dehalogenase DhaA, Journal of Biotechnology, 2017.
  11. Mejia‐Manzano, L.A., et al., Recovery of PEGylated and native lysozyme using an in situ aqueous two‐phase system directly from the PEGylation reaction, Journal of Chemical Technology and Biotechnology, 2017.
  12. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000420/WC500025941.pdf.
  13. Zhang, L., et al., Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer, Drug Delivery, 2016.
  14. Mayolo‐Deloisa, K., et al.,  PEGylated protein separation using different hydrophobic interaction supports: Conventional and monolithic supports. Biotechnology progress, 2016.
  15. Zhang, Y., et al., Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Scientific Reports, 2016, 6:21225.
  16. Mata-Gomez, M.A., et al., Modelling of electrokinetic phenomena for capture of PEGylated ribonuclease A in a microdevice with insulating structures, Biomicrofluidics, 2016, 10(3): 033106.
  17. Abbasi, S., et al., Design and cell cytotoxicity assessment of palmitoylated polyethylene glycol-grafted chitosan as nanomicelle carrier for paclitaxel. J. Appl. Polym. Sci., 2015, 133, 43233.
  18. Mayolo-Deloisa, K., et al., Aldehyde PEGylation of laccase from Trametes versicolor in route to increase its stability: effect on enzymatic activity, Journal of Molecular Recognition, 2015, 28(3): 173-179.
  19. Wu, L., et al., N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone, Molecular Pharmaceutics, 2015.
  20. Zaghmi, A., et al., Determination of the degree of PEGylation of protein bioconjugates using data from proton nuclear magnetic resonance spectroscopy, Data in Brief, V. 25, 2019, 104037.

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7 guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.